bisoprolol + trastuzumab

This is a combination of two drugs, bisoprolol and trastuzumab, used together primarily in the context of HER2-positive breast cancer treatment. Bisoprolol is a cardioselective beta-1 adrenergic receptor blocker commonly used to manage hypertension and heart failure. Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), overexpressed in certain breast cancers, and is indicated for HER2-positive breast cancer therapy. The combination has been studied for its potential to prevent or mitigate cardiotoxicity associated with trastuzumab therapy; clinical trials suggest that prophylactic use of bisoprolol can help preserve left ventricular ejection fraction during trastuzumab treatment but does not fully prevent cardiac remodeling[3][5]. This combination does not represent an approved fixed-dose pharmaceutical product but rather refers to concurrent administration as part of supportive care in oncology.

Brand names

Concor

Other names

bisoprolol fumaraterecombinant humanized anti-HER2 monoclonal antibody (trastuzumab)